Mortality and Major Neonatal Morbidity in Preterm Infants with Serious Congenital Heart Disease

Martina A Steurer1, Rebecca J Baer2, Christina D Chambers3

  • 1Department of Pediatrics, University of California San Francisco, San Francisco, CA; Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA; California Preterm Birth Initiative, University of California San Francisco, San Francisco, CA.

Insights

Mortality for preterm infants with serious congenital heart disease (CHD) decreased, but neonatal complications rose. Infants born at 28-32 weeks gestation faced the highest risks, highlighting the need for specialized neonatal care.

Area of Science:

  • Neonatalogy
  • Pediatric Cardiology
  • Public Health

Background:

  • Preterm infants with serious congenital heart disease (CHD) face significant health challenges.
  • Understanding trends in mortality and morbidity is crucial for improving care.

Purpose of the Study:

  • To investigate trends in 1-year mortality and neonatal morbidities in preterm infants with serious CHD.
  • To compare outcomes in preterm infants with and without CHD.

Main Methods:

  • A cohort study using a California population-based administrative dataset (2011-2017).
  • Inclusion of liveborn infants aged 26-36 weeks gestational age with serious CHD.
  • Assessment of 1-year mortality and major neonatal morbidities, including retinopathy of prematurity, bronchopulmonary dysplasia, necrotizing enterocolitis, intraventricular hemorrhage, and periventricular leukomalacia.

Main Results:

  • 1921 preterm infants with serious CHD were identified.
  • A 10.6% annual decrease in the relative risk (RR) of death (RR, 0.89) was observed.
  • An 8.3% annual increase in the RR of major neonatal morbidity (RR, 1.08) was noted.
  • Compared to infants without CHD, adjusted risk differences for mortality, morbidity, and combined outcomes were highest for gestational ages of 32, 28, and 30 weeks, respectively.

Conclusions:

  • Mortality in preterm infants with serious CHD decreased, while major neonatal morbidities increased.
  • Preterm infants born at 28-32 weeks gestational age exhibited the highest mortality and morbidity risks.
  • These findings underscore the necessity for specialized neonatal care for preterm infants with serious CHD.
Abstract

Related Concept Videos

Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
88
Mitral Regurgitation I: Introduction01:20

Mitral Regurgitation I: Introduction

Mitral regurgitation is characterized by the backward circulation of blood from the left ventricle to the left atrium during systole, a phase of the cardiac cycle when the heart contracts and pumps blood out of the chambers. This abnormal flow occurs primarily due to the dysfunction of the mitral valve or its supporting structures, which include the mitral leaflets, chordae tendineae, annulus, and papillary muscles.Etiology and Mechanisms:Primary Mitral Regurgitation: This type arises from...
94
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
3.1K
Cardiomyopathy VII: Pre and Post Operative Nursing Management01:28

Cardiomyopathy VII: Pre and Post Operative Nursing Management

Patients with hypertrophic cardiomyopathy (HCM) and left ventricular outflow tract (LVOT) obstruction who remain symptomatic despite optimal medical therapy may undergo a septal myectomy (Morrow procedure). This procedure involves excising a portion of the hypertrophied septum below the aortic valve using a heart-lung machine to improve blood flow through the LVOT. Effective preoperative and postoperative nursing management ensures successful patient outcomes, minimizes complications, and...
66
Fetal Circulation01:14

Fetal Circulation

Fetal circulation is a unique system that facilitates the exchange of gases, nutrients, and waste products between the developing fetus and the mother. This intricate process takes place through a special organ called the placenta.
Two umbilical arteries transport blood from the fetus to the placenta. At the placenta, the blood absorbs oxygen and nutrients while simultaneously eliminating waste products. This oxygen-enriched and nutrient-rich blood then returns to the fetus through one...
1.7K
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
97